Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation.

about

Critical analysis on the present methods for brain volume measurements in multiple sclerosis.Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments.

P2860

Q39459514-5C9583A2-5BE0-4FA8-A56B-4C6F6359FCA7 Q47188693-A3A5E387-E5C9-4E75-B4B1-F7881EB09E67

P2860

Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation.

Item

http://www.wikidata.org/entity/Q41490523

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Brain Atrophy as a Measure of ...... is: Influence of Inflammation.

@en

type

Item

label

Brain Atrophy as a Measure of ...... is: Influence of Inflammation.

@en

prefLabel

Brain Atrophy as a Measure of ...... is: Influence of Inflammation.

@en

P1476

Brain Atrophy as a Measure of ...... sis: Influence of Inflammation

@en

P2093

Caterina Mainero

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

Clinical relevance of brain volume measures in multiple sclerosis.

Gray matter pathology in (chronic) MS: modern views on an early observation.

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.

The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.

Brain perfusion by arterial spin labeling MRI in multiple sclerosis.

Brain atrophy in natalizumab-treated patients: A 3-year follow-up.

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

P304

226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FNHUM.2016.00226

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tatiana Koudriavtseva

P577

2016-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27242489

http://www.w3.org/2001/XMLSchema#string

P932

4865512

http://www.w3.org/2001/XMLSchema#string

Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation.

about

P2860

P2860

Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932